Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Bellicum Pharmaceuticals Inc's Business Segments
Bellicum Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Bellicum Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- License99.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 1 | 99.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel cellular immunotherapies for treating various forms of cancer and other serious and life-threatening conditions. The company, founded in 2004 and headquartered in Houston, Texas, utilizes its proprietary technology known as GoCAR-T® and GoTCR™ to engineer and modify immune cells, allowing them to recognize and kill cancer cells more effectively.
Bellicum's lead product candidates include BPX-601, BPX-603, and BPX-802. BPX-601 is an autologous GoCAR-T product candidate designed to target solid tumors expressing prostate stem cell antigen (PSCA), and it is being developed for treating patients with unresectable pancreatic cancer or gastric cancer. BPX-603 is an autologous GoCAR-T product candidate developed to treat patients with HER2-expressing solid tumors. BPX-802, on the other hand, is an allogeneic GoCAR-T product candidate targeting hematological cancers and solid tumors.
The company's central technology, GoCAR-T, allows for the precise control of immune cell activation and expansion, addressing potential safety concerns associated with other CAR-T approaches. This technology is designed to provide unique activation and inactivation capabilities, enabling the physician to control the activity of engineered immune cells in a patient's body.
Bellicum's GoTCR technology, which stands for Gigabase outer segment T cell receptor, aims to develop T cell receptor (TCR) products more precisely and effectively than traditional methodologies. The GoTCR technology incorporates a switchable safety feature called iMC (inducible MyD88/CD40), which can be activated to quickly address safety concerns related to TCR therapies.
Beyond its GoCAR-T and GoTCR programs, Bellicum Pharmaceuticals is also actively engaged in developing other cell therapies and cell-based products targeting various indications, such as hematological cancers, solid tumors, and orphan diseases. The company has collaborations with leading academic institutions, including Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, to further advance its pipeline and research efforts.
Bellicum Pharmaceuticals has a robust Intellectual Property (IP) portfolio, including patents related to its GoCAR-T and GoTCR technologies, which provide the company with a competitive advantage in the rapidly growing field of cellular immunotherapies. The company is focused on advancing its pipeline through clinical trials and obtaining regulatory approvals for its product candidates in order to bring these potentially life-saving therapies to patients in need.
Overall, Bellicum Pharmaceuticals Inc. is a pioneering biopharmaceutical company that utilizes innovative technologies to develop targeted and controllable cellular immunotherapies for the treatment of cancer and other serious diseases. With a strong pipeline, cutting-edge technology, and strategic collaborations, the company is well-positioned to make a significant impact in the field of cellular immunotherapies.
Bellicum's lead product candidates include BPX-601, BPX-603, and BPX-802. BPX-601 is an autologous GoCAR-T product candidate designed to target solid tumors expressing prostate stem cell antigen (PSCA), and it is being developed for treating patients with unresectable pancreatic cancer or gastric cancer. BPX-603 is an autologous GoCAR-T product candidate developed to treat patients with HER2-expressing solid tumors. BPX-802, on the other hand, is an allogeneic GoCAR-T product candidate targeting hematological cancers and solid tumors.
The company's central technology, GoCAR-T, allows for the precise control of immune cell activation and expansion, addressing potential safety concerns associated with other CAR-T approaches. This technology is designed to provide unique activation and inactivation capabilities, enabling the physician to control the activity of engineered immune cells in a patient's body.
Bellicum's GoTCR technology, which stands for Gigabase outer segment T cell receptor, aims to develop T cell receptor (TCR) products more precisely and effectively than traditional methodologies. The GoTCR technology incorporates a switchable safety feature called iMC (inducible MyD88/CD40), which can be activated to quickly address safety concerns related to TCR therapies.
Beyond its GoCAR-T and GoTCR programs, Bellicum Pharmaceuticals is also actively engaged in developing other cell therapies and cell-based products targeting various indications, such as hematological cancers, solid tumors, and orphan diseases. The company has collaborations with leading academic institutions, including Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, to further advance its pipeline and research efforts.
Bellicum Pharmaceuticals has a robust Intellectual Property (IP) portfolio, including patents related to its GoCAR-T and GoTCR technologies, which provide the company with a competitive advantage in the rapidly growing field of cellular immunotherapies. The company is focused on advancing its pipeline through clinical trials and obtaining regulatory approvals for its product candidates in order to bring these potentially life-saving therapies to patients in need.
Overall, Bellicum Pharmaceuticals Inc. is a pioneering biopharmaceutical company that utilizes innovative technologies to develop targeted and controllable cellular immunotherapies for the treatment of cancer and other serious diseases. With a strong pipeline, cutting-edge technology, and strategic collaborations, the company is well-positioned to make a significant impact in the field of cellular immunotherapies.
Bellicum Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative cell therapies for the treatment of various types of cancers and other serious diseases. The company is known for its focus on harnessing the power of the immune system to fight diseases through advanced cellular immunotherapy.
Segments
Bellicum Pharmaceuticals operates primarily in the biotechnology and pharmaceutical segment, with a strong emphasis on cell therapy. The company is engaged in the research, development, and commercialization of novel therapies that leverage genetically modified T-cells. The key segments within the company can be broadly categorized into:
1. Clinical Development:
- In this segment, Bellicum focuses on advancing its product candidates through clinical trials to assess their efficacy and safety in various indications, primarily hematologic malignancies and solid tumors.
2. Research and Early Development:
- This segment encompasses the discovery and preclinical development of new therapeutic candidates. It involves in-depth research into cell therapy technologies, mechanisms of action, and potential applications for addressing unmet medical needs.
3. Commercialization:
- Once products receive market approval, Bellicum works on the commercialization strategy, including manufacturing, marketing, and collaborations with other pharmaceutical companies and academic institutions.
Products and Services
Bellicum’s portfolio includes several product candidates that are in various stages of development, as well as established technologies that support its therapeutic efforts.
Key Product Candidates:
1. BPX-501:
- BPX-501 is an engineered T-cell therapy that utilizes an innovative platform to target and treat patients with blood cancers, such as leukemias and lymphomas. The therapy is designed to enhance the body’s natural immune response, with a focus on patients who are undergoing a hematopoietic stem cell transplant.
2. BPX-601:
- This product candidate is designed for the treatment of patients with solid tumors expressing the prostate stem cell antigen (PSCA). BPX-601 employs a targeted approach using T-cells that have been genetically modified to attack cancerous cells expressing PSCA.
3. Dual Control Technology:
- Bellicum has developed proprietary dual control technology that enables precise modulation of T-cell activation and persistence. This technology consists of two components: the Go switch, which activates the T-cells upon treatment with a specific drug, and the safety switch, which can deactivate the T-cells in the event of severe adverse effects. This system is applicable to various CAR-T and TCR therapies.
4. Car-T Cell Therapy:
- Bellicum is also engaged in the development of CAR-T cell (Chimeric Antigen Receptor T-cell) therapies, focusing on improving the efficacy and safety profiles of existing CAR-T therapies.
Services:
1. Collaborative Research and Development:
- Bellicum often collaborates with academic institutions and pharmaceutical companies to co-develop therapies, share technologies, or conduct joint research initiatives.
2. Clinical Trial Management:
- The company actively manages and conducts clinical trials to assess the safety and efficacy of its product candidates. This includes patient recruitment, data collection, and regulatory compliance.
3. Regulatory Affairs and Consulting:
- Bellicum provides expertise in navigating the regulatory landscape surrounding biologics and cell therapies, assisting in submissions to health authorities for clinical trial investigations and marketing approvals.
4. Manufacturing and Production:
- Through strategic partnerships and in-house capabilities, Bellicum focuses on optimizing the manufacturing process for its cell therapies to ensure scalable production that meets quality and compliance standards.
Conclusion
Overall, Bellicum Pharmaceuticals Inc. is dedicated to transforming cancer treatment through the development of cutting-edge cell therapies. By leveraging its unique technologies and innovative approaches, the company aims to address significant unmet medical needs in oncology and expand the potential of immunotherapies. Each of their segments, products, and services reflects a commitment to advancing the science of cancer treatment while ensuring patient safety and efficacy in therapeutic outcomes.
Segments
Bellicum Pharmaceuticals operates primarily in the biotechnology and pharmaceutical segment, with a strong emphasis on cell therapy. The company is engaged in the research, development, and commercialization of novel therapies that leverage genetically modified T-cells. The key segments within the company can be broadly categorized into:
1. Clinical Development:
- In this segment, Bellicum focuses on advancing its product candidates through clinical trials to assess their efficacy and safety in various indications, primarily hematologic malignancies and solid tumors.
2. Research and Early Development:
- This segment encompasses the discovery and preclinical development of new therapeutic candidates. It involves in-depth research into cell therapy technologies, mechanisms of action, and potential applications for addressing unmet medical needs.
3. Commercialization:
- Once products receive market approval, Bellicum works on the commercialization strategy, including manufacturing, marketing, and collaborations with other pharmaceutical companies and academic institutions.
Products and Services
Bellicum’s portfolio includes several product candidates that are in various stages of development, as well as established technologies that support its therapeutic efforts.
Key Product Candidates:
1. BPX-501:
- BPX-501 is an engineered T-cell therapy that utilizes an innovative platform to target and treat patients with blood cancers, such as leukemias and lymphomas. The therapy is designed to enhance the body’s natural immune response, with a focus on patients who are undergoing a hematopoietic stem cell transplant.
2. BPX-601:
- This product candidate is designed for the treatment of patients with solid tumors expressing the prostate stem cell antigen (PSCA). BPX-601 employs a targeted approach using T-cells that have been genetically modified to attack cancerous cells expressing PSCA.
3. Dual Control Technology:
- Bellicum has developed proprietary dual control technology that enables precise modulation of T-cell activation and persistence. This technology consists of two components: the Go switch, which activates the T-cells upon treatment with a specific drug, and the safety switch, which can deactivate the T-cells in the event of severe adverse effects. This system is applicable to various CAR-T and TCR therapies.
4. Car-T Cell Therapy:
- Bellicum is also engaged in the development of CAR-T cell (Chimeric Antigen Receptor T-cell) therapies, focusing on improving the efficacy and safety profiles of existing CAR-T therapies.
Services:
1. Collaborative Research and Development:
- Bellicum often collaborates with academic institutions and pharmaceutical companies to co-develop therapies, share technologies, or conduct joint research initiatives.
2. Clinical Trial Management:
- The company actively manages and conducts clinical trials to assess the safety and efficacy of its product candidates. This includes patient recruitment, data collection, and regulatory compliance.
3. Regulatory Affairs and Consulting:
- Bellicum provides expertise in navigating the regulatory landscape surrounding biologics and cell therapies, assisting in submissions to health authorities for clinical trial investigations and marketing approvals.
4. Manufacturing and Production:
- Through strategic partnerships and in-house capabilities, Bellicum focuses on optimizing the manufacturing process for its cell therapies to ensure scalable production that meets quality and compliance standards.
Conclusion
Overall, Bellicum Pharmaceuticals Inc. is dedicated to transforming cancer treatment through the development of cutting-edge cell therapies. By leveraging its unique technologies and innovative approaches, the company aims to address significant unmet medical needs in oncology and expand the potential of immunotherapies. Each of their segments, products, and services reflects a commitment to advancing the science of cancer treatment while ensuring patient safety and efficacy in therapeutic outcomes.